A device for injecting an intraocular lens (IOL) into an eye, the device having an injector body including a lumen and an open tip wherethrough the IOL is expressed from the device. An IOL loading bay is located in the passageway wherein the IOL is positioned and compressed. The injector tip is dimensioned to allow the surgeon to choose an insertion depth between first, second and third transition points defined on the tip, the first and second transition points having a larger diameter than the third transition point which is located closer to the open tend of the tip. If the surgeon wishes to insert through a very small incision size (e.g., about 2.4 mm), the surgeon will insert the tip only up to the third transition point. The injector is stable during delivery of the IOL therethrough due to a spreading of the tip within the eye which effectively anchors the tip during IOL delivery.

Patent
   8535331
Priority
Mar 31 2004
Filed
Mar 31 2004
Issued
Sep 17 2013
Expiry
Oct 22 2028
Extension
1666 days
Assg.orig
Entity
Large
1
36
currently ok
1. An injector for delivering a foldable IOL into an eye, comprising:
an injector body having a tip comprising a first segment, a second segment and a third segment, the third segment extending to an open end of the injector body, the open end being adapted to permit the IOL to exit the injector into the eye,
at least one slot extending from the open end through the second segment and the third segment, the third segment connected to the second segment at a transition point, the transition point characterized by a change in taper of an outer dimension of the tip.
2. The injector of claim 1, wherein the third segment has a constant outer diameter.
3. The injector of claim 1, wherein the open end has a slanted face.
4. The injector of claim 1, wherein the at least one slot comprises at least two slots.
5. The injector of claim 4, further comprising a lumen extending through the tip, and two lumen grooves extending along the lumen, each of the slots colinearly extending from a corresponding one of the lumen grooves.
6. The injector of claim 5, further comprising a compressor drawer extending from a loading bay of the injector body, the drawer movable between an open position and a closed position.
7. The injector of claim 6, wherein the compressor drawer comprises a drawer groove.
8. The injector of claim 7, wherein the drawer groove is aligned with one of the lumen grooves.
9. The injector of claim 2, wherein the constant outer diameter is about 2.0 to 2.5 mm.
10. The injector of claim 9, wherein the change in taper is a discrete change in taper.
11. The injector of claim 1, wherein the first segment is unslotted.
12. The injector of claim 1, wherein the first segment has a different taper than the second segment.
13. The injector of claim 12, wherein the second segment has a constant outer diameter.
14. The injector of claim 1, wherein the first segment is configured to compress a lens transported therethrough.
15. The injector of claim 1, wherein the second segment has a greater taper than the third segment.
16. The injector of claim 1, comprising a second transition point between the first and the second segments, an outer diameter at the second transition point being larger than an outer diameter at the transition point between the third segment and the second segment.
17. The injector of claim 16, wherein the second transition point characterized by a change in taper of an outer dimension of the tip.
18. The injector of claim 17, wherein the at least one slot does not extend through the first segment.

The present invention relates to ophthalmic surgical devices and methods. More particularly, the present invention relates to a device and method for inserting an intraocular lens (IOL) into an eye.

IOLs are artificial lenses used to replace the natural crystalline lens of the eye when the natural lens has cataracts or is otherwise diseased. IOLs are also sometimes implanted into an eye to correct refractive errors of the eye in which case the natural lens may remain in the eye together with the implanted IOL. The IOL may be placed in either the posterior chamber or anterior chamber of the eye. IOLs come in a variety of configurations and materials. Some common IOL styles include the so-called open-looped haptics which include the three-piece type having an optic and two haptics attached to and extending from the optic; the one-piece type wherein the optic and haptics are integrally formed (e.g., by machining the optic and haptics together from a single block of material); and also the closed looped haptic IOLs. Yet a further style of IOL is called the plate haptic type wherein the haptics are configured as a flat plate extending from opposite sides of the optic. The IOL may be made from a variety of materials or combination of materials such as PMMA, silicone, hydrogels and silicone hydrogels, etc.

Various instruments and methods for implanting the IOL in the eye are known. In one method, the surgeon simply uses surgical forceps having opposing blades which are used to grasp the IOL and insert it through the incision into the eye. While this method is still practiced today, more and more surgeons are using more sophisticated IOL inserter devices which offer advantages such as affording the surgeon more control when inserting the IOL into the eye. IOL inserter devices have recently been developed with reduced diameter insertion tips which allow for a much smaller incision to be made in the cornea than is possible using forceps alone. Smaller incision sizes (e.g., less than about 3 mm) are preferred over larger incisions (e.g., about 3.2 to 5+mm) since smaller incisions have been attributed to reduced post-surgical healing time and complications such as induced astigmatism.

Since IOLs are very small and delicate articles of manufacture, great care must be taken in their handling. In order for the IOL to fit through the smaller incisions, they need to be folded and/or compressed prior to entering the eye wherein they will assume their original unfolded/uncompressed shape. The IOL inserter device must therefore be designed in such a way as to permit the easy passage of the IOL through the device and into the eye, yet at the same time not damage the delicate IOL in any way. Should the IOL be damaged during delivery into the eye, the surgeon will most likely need to extract the damaged IOL from the eye and replace it with a new IOL, a highly undesirable surgical outcome.

Thus, as explained above, the IOL inserter device must be designed to permit easy passage of the IOL therethrough. It is equally important that the IOL be expelled from the tip of the IOL inserter device and into the eye in a predictable orientation and manner. Should the IOL be expelled from the tip too quickly or in the wrong orientation, the surgeon must further manipulate the IOL in the eye which could result in trauma to the surrounding tissues of the eye. It is therefore highly desirable to have an inserter device which allows for precise loading of the IOL into the inserter device and which will pass and expel the IOL from the inserter device tip and into the eye in a controlled, predictable and repeatable manner.

To ensure controlled expression of the IOL through the tip of the IOL inserter device, the IOL must first be loaded into the IOL inserter device. The loading of the IOL into the inserter device is therefore a precise and very important step in the process. Incorrect loading of an IOL into the inserter device is oftentimes cited as the reason for a failed IOL delivery sequence. In a typical IOL inserter device, the IOL inserter utilizes a plunger having a tip which engages the IOL (which has been previously loaded and compressed into the inserter lumen) to pass it through the inserter lumen. The IOL thus interfaces with the plunger tip as well as the lumen of the inserter device. The lumen typically is dimensioned with a narrowing toward the open tip thereof in order to further compress the IOL as it is advanced through the lumen. The tip of the lumen is sized for insertion through the surgical incision which, as stated above, is presently preferred in the sub 3 mm range. Thus, an inserter lumen will typically be dimensioned larger at the load area of the IOL and gradually decrease in diameter to the tip of the lumen where the IOL is expressed into the eye. It will be appreciated that the compressed diameter of the IOL at the lumen tip is the same as the inner diameter of the lumen tip, preferably sub 3 mm as stated above. Each of these component interfaces are dynamic in the sense that the forces acting between the interfacing components (i.e., the IOL, the plunger tip and the inserter lumen) will vary as the IOL is pushed through the lumen. Control of these dynamic forces is therefore of utmost importance or otherwise the IOL may be damaged during delivery due to excessive compressive forces acting thereon. For example, as the IOL is advanced by the plunger through an ever-decreasing diameter lumen, the IOL is being compressed while at the same time the forces necessary to push the IOL through the lumen increase. This may lead to excessive force between the plunger tip and the IOL resulting in possible damage to the IOL and/or uncontrolled release of the IOL from the lumen tip. Also, the force of the plunger tip may cause the IOL to twist and/or turn as it is moved through the inserter whereby the force between the IOL and the plunger tip and/or the inserter lumen may uncontrollably increase to the point of IOL damage.

Various inserter devices have been proposed which attempt to address these problems, yet there remains a need for an IOL inserter and method which reliably places an IOL into an eye through a small incision and reduces the likelihood of IOL damage during delivery through the injector device.

The injector comprises a device body defining a longitudinal passageway (lumen) terminating at an open tip wherethrough the IOL is expressed from the injector into an eye. A plunger having a longitudinal plunger shaft and a plunger tip telescopes with the lumen of the device body. An opening is provided in the device body to access the lumen wherein an IOL is positioned. The injector includes means for compressing, rolling or otherwise forcing the IOL into a smaller cross-section for delivery through the injector. In one possible embodiment, the injector device includes a compressor drawer which extends laterally of the IOL loading bay of the injector body. The compressor drawer is movable between fully open and fully closed positions and is initially in the open position. Once the IOL is positioned in the opening or loading bay of the passageway, the compressor drawer is moved to the closed position which compresses the IOL. The plunger is advanced at the proximal end of the injector device causing the tip of the plunger to engage the proximal end of the compressed IOL. As the plunger is advanced further, the IOL is pushed through the open distal tip of the injector body and expressed into the eye in the intended manner.

For purposes of description, the tip may be considered as having four contiguous segments S1-S4 between the main body portion wherein the IOL is initially loaded into the device, and the open end of the tip. The first, proximal segment S1 is closest to the main body, the fourth, distal segment S4 includes the open tip, and the second and third segments S2, S3 extend sequentially therebetween. The first proximal segment S1 tapers gradually inwardly for a first length L1 to gradually further compress the IOL as it is being advanced by the plunger toward the open end of the tip. The second segment S2 preferably has a substantially constant diameter for a second length L2 which is preferably smaller than length L1. The juncture of the first and second lengths define a first transition point T1 having an outer diameter of about 2.7 mm to about 3.1 mm, and more preferably about 2.8 mm. Since the second segment S2 preferably remains constant in diameter, the IOL is not compressed any further as it is passed through this segment by the plunger and will not enlarge an incision of the same size. The third segment S3 tapers inwardly at a greater rate than the taper of segment S1 for a length L3 that is preferably smaller than L1 or L2. The juncture of the second and third segments S2, S3 define a second transition point T2 having an outer diameter the same as at T1. The fourth segment S4 preferably has a continuous cross-section extending for a length L4 also preferably smaller than L1 or L2, terminating in a slanted end face defining the open end of the tip. The juncture of the third and fourth segments S3, S4 defines a third transition point T3 that has an outer diameter in the range of about 2.0 to 2.6 mm and more preferably about 2.4 mm.

Some surgeons will use the injector device by inserting the tip up to the first or second transition points T1, T2 which have an outer diameter not exceeding about 3.0 mm. This means the incision in the eye need not be larger than about 3 mm. Current surgeon preference is to have an incision no larger than about 3 mm, and preferably sub 3 mm. Yet there are other surgeons that may prefer an even smaller incision size on the order of about 2.4 mm. For these surgeons, they may insert the tip up to only the third transition point T3 which, as stated above, has an outer diameter in the range of about 2.0 to 2.6 mm and more preferably about 2.4 mm.

At least one but preferably two slots extend from the second transition point T2 to the tip open end face. The slots reduce the hoop (radial) strength of the tip along the third and fourth segments for reasons explained below. The slots may colinearly extend from respective grooves extending along the inside wall of the lumen through the tip wherein opposite sides of the IOL optic slide during passage of the IOL through the device and into the eye. Since the slots reduce the hoop strength of the tip along segments S3 and S4, those segments can spread outwardly under the force exerted by the compressed IOL as it travels through those segments. For surgeons who prefer to insert the tip only up to the third transition point T3, the fourth segment S4 will spread open within the eye as the IOL is passed therethrough. This spreading action of this portion of the tip effectively “anchors” the inserted portion (segment S4) of the tip in the eye until the IOL has completely exited the device. This anchoring effect is important in preventing the surgeon from losing control of the IOL insertion process, especially in those circumstances where the surgeon prefers to insert only up to the point of the third transition point T3 to maintain a very small diameter incision (i.e., in the range of about 2.0 to 2.5 mm). To explain, with only a small length of the tip inserted through the incision (i.e., up to point T3), and without such anchoring of the tip within the eye, the force of the IOL exiting the tip may cause an inserter to decenter and/or kick back from the incision, possibly resulting in incorrect placement within the eye or the IOL expressing from the tip completely outside of the eye. The anchoring effect of the inventive tip thus ensures the tip will remain centered in the incision and in the eye until the IOL is completely expressed from the tip. Once the IOL is fully expressed from the tip into the eye, the resiliency of the tip causes the tip to return to its normal diameter allowing easy withdrawal from the eye with no stretching of the incision.

FIG. 1A is a perspective view of an exemplary IOL injector incorporating the inventive tip;

FIG. 1B is a cross-sectional view taken generally along the line 1B-1B in FIG. 1A showing the compressor drawer in the closed position and the IOL in the compressed condition;

FIG. 2 is an enlarged, fragmented, perspective view of the inventive tip;

FIG. 3 is a side elevational view thereof;

FIG. 4 is a top plan view thereof;

FIG. 5 is a bottom plan view thereof; and

FIG. 6 is a schematic representation of an eye showing the anchoring effect of the tip within the eye as an IOL is being expressed from the tip.

Referring to FIG. 1A, a representative IOL injector device is indicated generally by the reference numeral 10. The injector device 10 includes an injector body 12 having a longitudinal lumen 14 extending from the proximal end 16 to distal open end 18a thereof. The lumen may assume any desired cross-sectional shape although circular or oval shapes are preferred. Proximal end 16 may include a finger hold flange 17 preferably configured with a straight edge 17a as shown for resting device 10 on a flat surface. A plunger 20, having a distal plunger tip 22 and proximal thumb press 24, telescopes within lumen 14 for engaging and pushing the IOL 30 through lumen 14 and out of distal tip 18a. It is understood that the overall configuration of the injector body 12 may vary from that shown and described herein. It is furthermore understood that the components of the injector device 10 may be made of any suitable material (e.g., polypropylene) and may be wholly or partly opaque, transparent or translucent to better visualize the IOL within the injector device and the IOL delivery sequence.

Injector body 12 further includes an opening 26 which opens into lumen 14. Opening or “IOL loading bay” 26 accepts an IOL 30 therein for delivery of the IOL out distal tip 18a. In one possible embodiment, an IOL retainer 40 such as described in commonly owned copending application Ser. Nos. 10/651,785 and 10/813,862 incorporated herein by reference, is used for loading the IOL 30 into loading bay 26, it being understood other IOL loading methods may be employed (including simply placing IOL 30 in loading bay 26 with a pair of forceps, for example). As explained in more detail in these copending applications, the retainer 40 and IOL 30 may be coupled and packaged together or coupled to and packaged with an injector device 12 such that the surgeon or nurse need not handle and/or manipulate the IOL directly when loading the IOL 30 into the device 10. It is also understood that the IOL configuration shown and described herein is for discussion purposes only, and that the present invention is not to be limited thereby. The invention may be easily adapted to IOLs of any configuration and type (e.g., IOLs with plate, open or closed loop haptics, anterior chamber IOLs, posterior chamber IOLs, accommodating IOLs (including single and double lens types), etc.).

Referring still to FIG. 1A, the plunger tip 22 is configured for engaging the IOL optic 31 at the periphery 31a thereof as the plunger 20 is advanced toward the tip opening 18a of the injector body 12. It is understood that other plunger tip designs may be used with the present invention as desired. It is furthermore preferred that the plunger shaft is rotationally fixed within lumen 14 to prevent unexpected rotation of the shaft (and thus the tip 22) with the lumen 14. The plunger shaft may be rotationally fixed by forming the proximal shaft length 20b and lumen 14 non-circular in cross-section or by including rotational fixing elements on the lumen inner wall and plunger shaft (e.g., longitudinal flange on the plunger having a sliding fit within a longitudinally extending groove provided on the lumen inner wall).

The injector includes means for compressing, rolling or otherwise forcing the IOL into a smaller cross-section for delivery through the injector. In the embodiment of FIG. 1A, the injector device includes a compressor drawer 60 which extends laterally of the IOL loading bay 26 of the injector body 12. The compressor drawer 60 is movable between fully open and fully closed positions and is initially in the open position to provide access to opening 26 for placement of the IOL therein. Referring to FIG. 1B, upon moving compressor drawer 60 to the fully closed position, the opposite edge of the optic periphery 31a becomes engaged in groove 60a of drawer 60. Thus, lumen 14 together with lumen groove 14a, drawer groove 60a, and drawer top wall 60b compresses and encases IOL optic 31 within lumen 14. The locating of the optic periphery 31a inside opposite grooves 14a and 60a ensures a planar delivery of the IOL 30 through lumen 14 and out tip 18. This manner of IOL planar delivery is described in more detail in commonly assigned U.S. Pat. No. 6,491,697.

Prior to closing compressor drawer 60 and compressing the IOL 30 inside the injector body, it may be desirable to apply viscoelastic to the area surrounding the IOL 30 to ease delivery of the IOL through the injector body. This is a common practice in the industry and the amount and location of viscoelastic application varies according to the instructions for use provided with the device as well as the desires of the surgeon. Once the viscoelastic has been applied as desired, the compressor drawer 60 is moved to the fully closed position whereupon the IOL optic 31 is compressed and ready for delivery through a small incision formed in an eye. The surgeon inserts the injector tip 18a into the incision cut into the eye (reference numeral 13 in FIG. 6) and begins advancing the plunger 20. As the plunger 20 is advanced, the plunger tip 22 engages the optic periphery 31a and pushes IOL 30 distally. Upon continued advancement of the plunger 20, the IOL 30 is pushed through the injector tip 18a and is finally expressed therefrom and into the eye 11 (FIG. 6).

For purposes of description, the injector tip may be considered as having four contiguous segments S1-S4 between the main body portion wherein the IOL is initially loaded into the device at an opening 26, and the open end of the tip 18a. It is understood that the tip may be separable from the main injector body or may be formed as a unitary construction therewith. The first, proximal segment S1 is closest to the main body 12, the fourth, distal segment S4 includes the open tip 18a, and the second and third segments S3, S3 extend sequentially therebetween. The first proximal segment S1 tapers gradually inwardly for a first length L1 (FIG. 1A.) to gradually further compress the IOL as it is being advanced by the plunger toward the open end of the tip 18a. The second segment S2 preferably has a substantially constant diameter for a second length L2 (FIGS. 2-5) which is preferably smaller than length L1. The juncture of the first and second segments S1, S2 define a first transition point T1 having an outer diameter of about 2.7 mm to about 3.1 mm, and more preferably about 2.8 mm. Since the second segment S2 preferably remains constant in diameter, the surgeon may insert the device anywhere along second segment S2 and not stretch the incision as would occur if this segment were tapered. Furthermore, the IOL is not compressed any further as it is passed through this segment by the plunger. The third segment S3 tapers inwardly at a greater rate than the taper of segment S1 for a length L3 that is preferably smaller than L1 or L2. The fourth segment S4 preferably has a continuous diameter extending for a length L4 also preferably smaller than L1 or L2, terminating in a slanted end face defining the open end of the tip 18a. The juncture of the third and fourth segments S3, S4 define a third transition point T3 having an outer diameter of about 2.0 mm to about 2.6 mm, and more preferably about 2.4 mm. Some surgeons will use the injector device by inserting the tip up to the first transition point T1 which has an outer diameter not exceeding about 3.0 mm and more preferably about 2.8 mm. This means the incision in the eye need not be larger than about 3 mm. Current surgeon preference is to have an incision no larger than about 3 mm, and preferably sub 3 mm. Yet there are other surgeons that may prefer an even smaller incision size on the order of about 2.4 mm. For these surgeons, they may insert the tip up to only the third transition point T3 as shown in FIG. 6 which, as stated above, has an outer diameter in the range of about 2.0 to 2.6 mm and more preferably about 2.4 mm.

At least one but preferably two slots 21a, 21b extend from the second transition point T2 to the tip open end face. The slots reduce the hoop (radial) strength of the tip along the third and fourth segments S3, S4 for reasons explained below. The slots may colinearly extend from respective grooves 14a, 14b (14b not shown but is coextensive with drawer groove 60a seen in FIG. 1B) extending along the inside wall of the lumen through the tip wherein opposite sides of the IOL optic periphery 31a slide during passage of the IOL through the device and into the eye. Since the slots reduce the hoop strength of the tip along segments S3, S4, the inserted segment S4 will spread outwardly under the force exerted by the compressed IOL as it travels through those segments as seen in FIG. 6. For surgeons who prefer to insert the tip only up to the third transition point T3, the spreading action of this portion of the tip effectively “anchors” the inserted portion (segment S4) of the tip in the eye until the IOL has completely exited the device. This anchoring effect is important in preventing the surgeon from losing control of the IOL insertion process, especially in those circumstances where the surgeon prefers to insert only up to the point of the third transition point T3 to maintain a very small diameter incision (i.e., in the range of about 2.0 to 2.5 mm). To explain, with only a small length of the tip inserted through the incision (i.e., only up to point T3), and without such anchoring of the tip within the eye, the force of the IOL exiting the tip may cause an inserter to decenter and/or kick back from the incision, possibly resulting in incorrect placement within the eye or the IOL expressing from the tip completely outside of the eye. The anchoring effect of the inventive tip thus ensures the tip will remain centered in the incision and in the eye until the IOL is completely expressed from the tip. Once the IOL is fully expressed from the tip into the eye, the resiliency of the tip causes the tip to return to its normal diameter (as seen in FIGS. 1-5) allowing easy withdrawal of the tip from the eye with no stretching of the incision.

The injector tip is thus dimensioned to allow the surgeon to choose an insertion depth between first, second or third transition points defined on the tip, with the first and second transition points being larger in diameter than the third transition point and all diameters being about or less than 3 mm. If the surgeon wishes to insert through an incision around or just below 3 mm, the surgeon may insert the device up to the first or second transition point T1, T2. If the surgeon instead wishes to insert through a very small incision size (e.g., about 2.4 mm), the surgeon will insert the tip only up to the third transition point T3 and the insertion device will remain stable owing to the unique anchoring design thereof.

Heyman, Thomas M., Vaquero, Edward

Patent Priority Assignee Title
11083568, Feb 07 2017 RXSIGHT, INC Intraocular lens inserter cartridge with an IOL-guiding structure
Patent Priority Assignee Title
4573998, Feb 05 1982 GREYHOUND FINANCIAL CAPITAL CORPORATION Methods for implantation of deformable intraocular lenses
4681102, Sep 11 1985 MASTELLONE, CHARLES; BARTELL, MICHAEL Apparatus and method for insertion of an intra-ocular lens
4702244, Feb 05 1982 GREYHOUND FINANCIAL CAPITAL CORPORATION Surgical device for implantation of a deformable intraocular lens
4706669, Jan 30 1984 Device for perforating the lens capsule front wall in the eye of living beings
4715373, Sep 27 1985 Devices for implantation of deformable intraocular lens structures
4765329, Oct 19 1987 REDWITZ & WILSON, INC , 151 KALMUS DRIVE, SUITE F, #1, COSTA MESA, CALIFORNIA 92626, A CORP OF CA Intraocular lens insertion instrument
4834094, Oct 07 1987 Patton Medical Technologies, Inc.; PATTON MEDICAL TECHNOLOGIES, INC , "Canoe" apparatus for inserting intra-ocular lens into the eye
4836201, Mar 24 1988 Patton Medical Technologies, Inc.; PATTON MEDICAL TECHNOLOGIES, INC "Envelope" apparatus for inserting intra-ocular lens into the eye
4919130, Nov 07 1986 NESTLE S A Tool for inserting compressible intraocular lenses into the eye and method
4926877, Apr 24 1989 Biopsy needle with completely closable cutting end bore
4934363, Dec 15 1987 Iolab Corporation Lens insertion instrument
5123905, Jun 07 1991 KELMAN, ANN G Intraocular lens injector
5190552, Feb 04 1992 Slotted tube injector for an intraocular lens
5275604, Dec 03 1992 Abbott Medical Optics Inc Contoured duct apparatus and method for insertion of flexible intraocular lens
5304182, Sep 23 1992 Abbott Medical Optics Inc Apparatus and method for curling and inserting flexible intraocular lenses
5312413, Jul 17 1991 Instrumentation for ophthalmic surgery and method of using the same
5425734, Jul 02 1993 Abbott Medical Optics Inc Intraocular lens injector
5474562, Mar 09 1993 Chiron Vision Corporation Apparatus and method for preparing an intraocular lens for insertion
5494484, Sep 30 1992 STAAR Surgical Company Deformable intraocular lens injecting device
5496328, Jul 15 1993 STAAR JAPAN INC Inserting device for deformable intraocular lens
5499987, Sep 30 1992 STAAR Surgical Company Deformable intraocular lens cartridge
5772666, Feb 15 1994 STAAR SURGICAL COMPANY, INC Deformable intraocular lens injecting apparatus with deformable tip plunger
5810834, Oct 07 1996 Bausch & Lomb Incorporated Tip formation for inserting a flexible membrane into an eye
5876406, Aug 02 1996 STAAR SURGICAL COMPANY, INC Deformable intraocular lens injecting apparatus with transverse hinged lens cartridge
6010510, Jun 02 1998 Novartis AG Plunger
6056757, Feb 14 1994 STAAR SURGICAL COMPANY, INC Implantation device with deformable nozzle tip for implanting a deformable intraocular lens
6387101, Oct 22 1999 STAAR SURGICAL COMPANY, INC Deformable intraocular lens injecting apparatus and method
6447520, Mar 19 2001 JOHNSON & JOHNSON SURGICAL VISION, INC IOL insertion apparatus with IOL engagement structure and method for using same
6491697, Sep 26 1996 Bausch & Lomb Incorporated Method and apparatus for inserting a flexible membrane into an eye
20020022881,
20020193805,
20030216745,
EP270257,
JP5103808,
WO164147,
WO3077805,
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Mar 31 2004Bausch & Lomb Incorporated(assignment on the face of the patent)
Jun 29 2004VAQUERO, EDWARDBausch & Lomb IncorporatedASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0148080251 pdf
Jul 15 2004VAQUERO, EDWARDBausch & Lomb IncorporatedASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0150730608 pdf
Jul 15 2004HEYMAN, THOMAS M Bausch & Lomb IncorporatedASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0150730608 pdf
Oct 26 2007BAUSCH & LOMB REALTY CORPORATIONCREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007BAUSCH & LOMB TECHNOLOGY CORPORATIONCREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007BAUSCH & LOMB INTERNATIONAL INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007BAUSCH & LOMB CHINA, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007BAUSCH & LOMB SOUTH ASIA, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007SIGHT SAVERS, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007WILMINGTON MANAGEMENT CORP CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007WILMINGTON PARTNERS L P CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L MINORITY DUTCH HOLDINGS LLCCREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007Iolab CorporationCREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007RHC HOLDINGS, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007WP PRISM, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L VPLEX HOLDINGS, INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L SPAF INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B & L DOMESTIC HOLDINGS CORP CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L CRL PARTNERS L P CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L CRL INC CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007Bausch & Lomb IncorporatedCREDIT SUISSESECURITY AGREEMENT0201220722 pdf
Oct 26 2007B&L FINANCIAL HOLDINGS CORP CREDIT SUISSESECURITY AGREEMENT0201220722 pdf
May 18 2012Credit Suisse AG, Cayman Islands BranchBausch & Lomb IncorporatedRELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS 0287260142 pdf
May 18 2012Bausch & Lomb IncorporatedCITIBANK N A , AS ADMINISTRATIVE AGENTSECURITY AGREEMENT0287280645 pdf
May 18 2012EYEONICS, INC CITIBANK N A , AS ADMINISTRATIVE AGENTSECURITY AGREEMENT0287280645 pdf
Aug 05 2013CITIBANK N A , AS ADMINISTRATIVE AGENTWP PRISM INC N K A BAUSCH & LOMB HOLDINGS INC RELEASE OF SECURITY INTEREST0309950444 pdf
Aug 05 2013CITIBANK N A , AS ADMINISTRATIVE AGENTBausch & Lomb IncorporatedRELEASE OF SECURITY INTEREST0309950444 pdf
Aug 05 2013CITIBANK N A , AS ADMINISTRATIVE AGENTISTA PHARMACEUTICALSRELEASE OF SECURITY INTEREST0309950444 pdf
Aug 30 2013Bausch & Lomb IncorporatedGOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENTSECURITY AGREEMENT0311560508 pdf
Jan 08 2015GOLDMAN SACHS LENDING PARTNERS, LLCBARCLAYS BANK PLC, AS SUCCESSOR AGENTNOTICE OF SUCCESSION OF AGENCY0347490689 pdf
Jul 17 2017Bausch & Lomb IncorporatedThe Bank of New York MellonSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0432510932 pdf
Feb 13 2018Valeant Pharmaceuticals InternationalTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018VALEANT PHARMACEUTICALS NORTH AMERICA LLCTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018WIRRA IP PTY LIMITEDTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018VALEANT PHARMA POLAND SP Z O O THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018VALEANT PHARMACEUTICALS LUXEMBOURG S A R L THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018VALEANT PHARMACEUTICALS IRELAND LIMITEDTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018ORAPHARMA, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT CANADA LPTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018ATON PHARMA, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018SYNERGETICS USA, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018Technolas Perfect Vision GmbHBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT CANADA LPBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018Valeant Pharmaceuticals InternationalBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT PHARMACEUTICALS NORTH AMERICA LLCBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018WIRRA IP PTY LIMITEDBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT PHARMA POLAND SP Z O O BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT PHARMACEUTICALS LUXEMBOURG S A R L BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018VALEANT PHARMACEUTICALS IRELAND LIMITEDBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018SOLTA MEDICAL, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018SANTARUS, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018Salix Pharmaceuticals, LtdBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018Bausch & Lomb IncorporatedBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018BAUSCH & LOMB PHARMA HOLDINGS CORP BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018COMMONWEALTH LABORATORIES, LLCBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018DOW PHARMACEUTICAL SCIENCES, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018ECR PHARMACEUTICALS CO , INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018LABORATOIRE CHAUVIN S A S BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018Medicis Pharmaceutical CorporationBARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018ONPHARMA INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018PRECISION DERMATOLOGY, INC BARCLAYS BANK PLC, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440299 pdf
Feb 13 2018ATON PHARMA, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018Bausch & Lomb IncorporatedTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018BAUSCH & LOMB PHARMA HOLDINGS CORP THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018SYNERGETICS USA, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018SOLTA MEDICAL, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018SANTARUS, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018Salix Pharmaceuticals, LtdTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018PRECISION DERMATOLOGY, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018ORAPHARMA, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018Technolas Perfect Vision GmbHTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018COMMONWEALTH LABORATORIES, LLCTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018DOW PHARMACEUTICAL SCIENCES, INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018ECR PHARMACEUTICALS CO , INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018LABORATOIRE CHAUVIN S A S THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018Medicis Pharmaceutical CorporationTHE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Feb 13 2018ONPHARMA INC THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0454440634 pdf
Mar 08 2019ORAPHARMA, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019BAUSCH HEALTH AMERICAS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019Bausch & Lomb IncorporatedTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019BAUSCH HEALTH US, LLCTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019SOLTA MEDICAL, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019PRECISION DERMATOLOGY, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019SALIX PHARMACEUTICALS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019SANTARUS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Mar 08 2019Medicis Pharmaceutical CorporationTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0485560758 pdf
Jun 08 2021ORAPHARMA, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021BAUSCH HEALTH AMERICAS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021PRECISION DERMATOLOGY, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021SANTARUS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021SALIX PHARMACEUTICALS, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021Medicis Pharmaceutical CorporationTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021SOLTA MEDICAL, INC THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021BAUSCH HEALTH US, LLCTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Jun 08 2021Bausch & Lomb IncorporatedTHE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0568110814 pdf
Feb 10 2022SANTARUS, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022ORAPHARMA, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022PRECISION DERMATOLOGY, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022BAUSCH HEALTH AMERICAS, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022SALIX PHARMACEUTICALS, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022Medicis Pharmaceutical CorporationThe Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022SOLTA MEDICAL, INC The Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022BAUSCH HEALTH US, LLCThe Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
Feb 10 2022Bausch & Lomb IncorporatedThe Bank of New York MellonSECURITY AGREEMENT0591210001 pdf
May 10 2022Bausch & Lomb IncorporatedCITIBANK, N A AS COLLATERAL AGENTPATENT SECURITY AGREEMENT0599130548 pdf
Oct 18 2022The Bank of New York MellonTechnolas Perfect Vision GmbHOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 0618720295 pdf
Oct 18 2022The Bank of New York MellonLABORATOIRE CHAUVIN S A S OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 0618720295 pdf
Oct 18 2022The Bank of New York MellonThe United States of America, as represented by the Secretary, Department of Health and Human ServicesOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 0618720484 pdf
Oct 18 2022The Bank of New York MellonTechnolas Perfect Vision GmbHOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 0618720484 pdf
Oct 18 2022The Bank of New York MellonBausch & Lomb IncorporatedOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 0618720295 pdf
Oct 18 2022The Bank of New York MellonTechnolas Perfect Vision GmbHOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 043251 0932 0618720099 pdf
Oct 18 2022The Bank of New York MellonBausch & Lomb IncorporatedOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 043251 0932 0618720099 pdf
Oct 18 2022The Bank of New York MellonBausch & Lomb IncorporatedOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 059121 0001 0618730001 pdf
Oct 18 2022The Bank of New York MellonBAUSCH HEALTH COMPANIES INC OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 0618720484 pdf
Oct 18 2022The Bank of New York MellonBausch & Lomb IncorporatedOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 056811 0814 0618720669 pdf
Oct 18 2022The Bank of New York MellonBausch & Lomb IncorporatedOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 0618720484 pdf
Oct 18 2022The Bank of New York MellonThe United States of America, as represented by the Secretary, Department of Health and Human ServicesOMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 0618720295 pdf
Oct 19 2022BARCLAYS BANK PLCBausch & Lomb IncorporatedRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 0617790001 pdf
Oct 19 2022BARCLAYS BANK PLCTechnolas Perfect Vision GmbHRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 0617790001 pdf
Oct 19 2022BARCLAYS BANK PLCThe United States of America, as represented by the Secretary, Department of Health and Human ServicesRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 0617790001 pdf
Oct 19 2022BARCLAYS BANK PLCBausch & Lomb IncorporatedRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 031156 0508 0617780446 pdf
Oct 19 2022BARCLAYS BANK PLCLABORATOIRE CHAUVIN S A S RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 0617790001 pdf
Oct 19 2022BARCLAYS BANK PLCPF Consumer Healthcare 1 LLCRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 0617790001 pdf
Oct 19 2022BARCLAYS BANK PLCBausch & Lomb IncorporatedRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 0617780146 pdf
Oct 19 2022BARCLAYS BANK PLCUniversity of RochesterRELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 0617780146 pdf
Sep 29 2023Bausch & Lomb IncorporatedCITIBANK, N A , AS NOTES COLLATERAL AGENTPATENT SECURITY AGREEMENT0651200086 pdf
Date Maintenance Fee Events
Feb 27 2017M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
Feb 24 2021M1552: Payment of Maintenance Fee, 8th Year, Large Entity.


Date Maintenance Schedule
Sep 17 20164 years fee payment window open
Mar 17 20176 months grace period start (w surcharge)
Sep 17 2017patent expiry (for year 4)
Sep 17 20192 years to revive unintentionally abandoned end. (for year 4)
Sep 17 20208 years fee payment window open
Mar 17 20216 months grace period start (w surcharge)
Sep 17 2021patent expiry (for year 8)
Sep 17 20232 years to revive unintentionally abandoned end. (for year 8)
Sep 17 202412 years fee payment window open
Mar 17 20256 months grace period start (w surcharge)
Sep 17 2025patent expiry (for year 12)
Sep 17 20272 years to revive unintentionally abandoned end. (for year 12)